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ABSTRACT
Myopericytoma is a rare tumour arising from myopericytes. Myopericytes are transitional cells between 
pericytes, which are perivascular cells adjacent to capillaries, and vascular smooth muscle cells. We report 
a case of cutaneous myopericytoma metastasising to the right kidney. It represents one of the few cases 
of malignant behaviour in myopericytoma, and is the first report of a myopericytoma metastasising to 
the urinary tract. This case suggests that the traditional view that urinary myopericytoma are benign 
lesions needs to be updated.
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INTRODUCTION
Myopericytoma is a rare tumour that arises 
from myopericytes. Myopericytes are transitional 
cells between pericytes, which are perivascular 
cells adjacent to capillaries and vascular smooth 
muscle cells. The term myopericytes was first 
used by Dictor et al.1 in 1992 to describe a subset 
of myofibroblasts, and a few years later, the term 
myopericytoma was proposed by Requena et al.2 
The immunohistochemical characteristics were 
described by Granter et al.3 in 1998.2 Histologically, 
these tumours are characterised by concentric 
perivascular proliferation of spindle cells. 
Myopericytomas form a morphological spectrum of 
tumours with infantile haemangiomyopericytoma, 
solitary myofibroma, myofibromatosis, and 
myopericytoma; all of which show differentiation 
towards perivascular myoid cells or pericytes. 
In 2002, the World Health Organization (WHO) 
categorised these tumours under the group 
‘pericytic/perivascular tumours’.4
We report a case of cutaneous myopericytoma 
metastasising to the right kidney; this represents 
one of the few cases of a malignant behaviour 
in a myopericytoma, and the first case of 
a myopericytoma further metastasising to the 
urinary tract.
CASE REPORT 
In November 2012, a 47-year-old woman consulted 
her dermatologist about a skin lesion in the upper 
middle quadrant of the right breast. The lesion was 
only slightly elevated and not well demarcated, 
with a purple angiomatous aspect. As the skin 
lesion was rapidly growing and presented an 
aesthetic problem, the woman was referred to a 
plastic surgeon for excision. 
The lesion and a part of the underlying subcutis 
were removed with a minimal, lesion-free 
resection margin in December 2012. Microscopic 
examination showed a myopericytoma with atypical 
morphological features. Due to the presence of a 
high mitotic index (14/10 high power fields) and the 
presence of satellite nodules in the subcutaneous 
tissue, as well as uncertainty of the biological 
behaviour of the lesion, a broad resection was 
performed. The section margins were tumour free 
and no additional staging was performed.
In 2014, the patient consulted a second 
plastic surgeon for aesthetic correction of the 
postoperative scar and palpation of a new mass 
underneath this scar. Clinical examination showed 
a hard, well-circumscribed mass in the right 
upper quadrant of the right breast. Clinically, the 
tumour was not adherent to the skin but possibly 
adherent to the underlying pectoralis muscle. A 
very broad resection of the lesion was performed 
with stripping of a pectoralis muscle patch. 
Anatomopathological results revealed necrotic 
material, which was impossible to differentiate, 
surrounded by an inflammatory reaction. Resection 
margins were free of tumour and no additional 
staging was performed.
Figure 1:  (A,B) Computed tomography scan showing a malignant solid renal tumour of the kidney with 
irregular contrast captation. (C) Haematoxylin and eosin staining of the kidney lesion showing a  highly 
cellular tumour (100x) (D) Hematoxylin and eosin staining of the original skin lesion showing morphology 
comparable to the kidney lesion (E) Immunohistochemical expression of CD34 in the original skin 
lesion (F) Focal immunohistochemical expression of alpha smooth muscle actin in the original skin 
lesion (G) Negative desmin control with internal positive control of arrector pili muscles in the original 






In July 2015, the patient was referred to the 
department of internal medicine by her family 
doctor with weight loss of 8 kg, persistent fatigue, 
and pain in the right hypochondriac region. There 
were no urinary symptoms. Clinical examination 
revealed tenderness in the right hypochondriac 
region, and ultrasonography showed a mass on 
the upper pole of the right kidney. A computed 
tomography (CT) scan of the abdomen revealed 
a voluminous tumour of 8.2 cm in the upper pole 
of the right kidney. The tumour showed irregular 
contrast captation and was assessed as a malignant 
solid renal tumour, presumably renal cell carcinoma. 
No pathologically enlarged retroperitoneal nodes 
were seen (Figure 1A and 1B). A CT image of the 
thorax showed no abnormalities. A radical right 
nephrectomy was performed with an uncomplicated 
postoperative course.
Pathologic examination, however, showed 
no renal cell carcinoma, but a high-grade 
sarcomatous lesion. The tumour cells were 
polygonal or spindle shaped, with areas of 
necrosis and numerous mitoses. The cells were 
arranged in short fascicles, sometimes with a 
hemangiopericytoma-like pattern (Figure 1C). The 
kidney lesion was compared with the original skin 
tumour and showed similar morphology upon 
haematoxylin and eosin staining (Figure 1D), and 
immunohistochemistry (Figure 1E–H).
Immunohistochemical analysis revealed expression 
of CD34 (Dako Clone QBEnd 10) (Figure 1E), and 
only focal expression of myogenic markers such as 
smooth muscle actin (Dako Clone 1A4) (Figure 1F) 
and calponin (Dako Clone CALP). The tumour was 
negative for desmin (Dako Clone D33) (Figure 1G) 
and the ETS-related gene (Dako Clone EP111) 
(Figure 1H). These findings are compatible 
with a high-grade sarcoma with myopericytic 
differentiation. Both tumours showed a high mitotic 
index. The initial skin tumour showed low-grade 
cytonuclear atypia, while the kidney tumour showed 
a high grade of atypia.
Next generation sequencing was performed on 
the kidney lesion but no BRAF mutation was 
present.5 Resection margins were free of tumour 
and no adjuvant therapy was given. A positron 
emission tomography (PET) CT conducted after 
3 months (October 2015) showed no evidence of 
disseminated disease so far.
DISCUSSION 
A myopericytoma is a rare tumour mostly arising 
in skin or superficial soft tissues. The largest case 
series of 54 patients was described by Mentzel et 
al.5 in 2006. In their series, 26 cases occurred in the 
lower extremities, 16 in the upper extremities, 4 in 
the head and neck region, and 2 in the trunk.5 The 
presence of myopericytoma in visceral organs is 
rare, although occasional cases have been described 
in the thorax, lungs, heart, gastrointestinal tract, 
brain, and urinary tract.6 Myopericytomas may have 
a tendency to recur locally, but most are benign 
tumours with an excellent prognosis.
Our case report of a myopericytoma is exceptional 
because of its location, namely the urinary tract. 
A search of English literature using the Medline 
database via PUBMED revealed 11 other cases of 
urinary myopericytoma (Table 1).7-11 Within this 
literature, all but one of these tumours occurred in 
the kidney; in one case the urinary bladder was 
affected. The majority of the tumours were small, 
with a mean diameter of 5.5 cm and a median 
diameter of 4.5 cm. Commonly, the lesions were 
incidental findings on imaging studies; though, 
in one case of a large mass of the left kidney, the 
lesion was found during clinical examination. 
Frequency, dysuria, or abdominal/flank pain have 
also been described. The age of patients diagnosed 
with urinary myopericytoma was variable, with 
the youngest patient being a 33-year-old male. 
None of these patients developed any evidence 
of recurrent or metastatic disease after surgical 
removal of the lesion (mean follow-up: 30 months).
Our case concerned a malignant myopericytoma. 
In contrast to the typical myopericytoma, this 
tumour has atypical features such as a high mitotic 
index, nuclear pleomorphism, necrosis, and high 
cellularity. In 2002, McMenamin and Fletcher12 
named these tumours malignant myopericytomas. 
Incidence of these tumours is extremely rare; to our 
knowledge, only eight cases have been described 
in the literature (Table 2).5,12-14 The majority of 
these tumours appear to be located superficially, 
with only the skin and subcutaneous tissue 
affected. To date, only single cases of malignant 
mediastinal myopericytoma, malignant left 
atrial myopericytoma, and malignant intradural 
myopericytoma have been described.12-14 
Table 1: Myopericytoma of the urinary tract.











Lau et al. 20107 59/F Left kidney 3.5 Incidental finding Partial nephrectomy 8
Dhingra et al. 
20128 40/F Left kidney 3.8
Left flank pain and 
frequency Partial nephrectomy 24
Zhao et al. 20149
59/F Left kidney 3.5 Incidental finding Radical nephrectomy 14
52/F Urinary bladder 6 Frequency and dysuria Partial cystectomy 39
Zhang et al. 
201420 39/M Left kidney 18
Painless mass left 
abdomen Radical nephrectomy + LD 20
Li et al. 201511
56/F Right kidney 1.8 Pain on the right side of the abdomen Partial nephrectomy 66 
33/M Left kidney 4.5 Incidental finding Radical nephrectomy 64
46/M Left kidney 7.3 Incidental finding Radical nephrectomy 46
70/M Left kidney 4.8 Incidental finding Radical nephrectomy 16
69/M Right kidney 4.2 Incidental finding Radical nephrectomy 14
59/M Left kidney 3.6 Incidental finding Radical nephrectomy 26
Table 2: Malignant myopericytoma.
F: female; M: male; L5: lumbar 5; S1: sacral 1; NS: not specified; IM: intermuscular; SVC: superior vena 
cava; LFV: left field of vision; EBRT: external beam radiation therapy; ANRM: alive with no evidence of 





Location Size (mm) Symptoms Treatment ANRM Outcome
McMenamin 
et al. 200212
80/F Left side  of neck 20
Painless rapidly 
growing mass Marginal excision
Alive with liver metastases 
at 14 months
46/M Left thigh 130 Painful deep-seated IM mass
Wide local  
excision + EBRT
Death at 7 months with 
liver, brain, and heart 
metastases at 6 months
19/F Heel of  right foot 40 Painful mass
Below knee 
amputation Death within 1 year
81/M Left arm 15 Painless mass Wide local excision ANRM at 18 months
67/M
Mediastinal 






Excision of skin 
nodule
Death within 1 month with 
subcutaneous and  
skin metastases
Mentzel et 
al. 20065 61/M Lower leg NS
Painless 
subcutaneous mass Wide local excision
ANRM. Period  
not specified.
Mainville et 
al. 201513 52/M Left atrium NS
Blackening of  
the LFV Excision atrial mass
Alive with brain, skeletal,  
and liver metastasis  
at 8 months




Pain right dorsal 
calf Excision atrial mass ANRM at 18 months
Van Besien 







Weight loss, fatigue, 
flank pain
Excision of skin 
nodule and  
kidney metastasis
ANRM at 3 months
Although metastasis of a malignant myopericytoma 
to the liver, brain, skeletal system, and heart have 
previously been described, this report represents 
the first described case of a metastasis of a 
malignant myopericytoma in the urinary tract.
Benign myopericytomas are diagnosed by 
excisional biopsy. The pathological result is often a 
surprise to the treating physician due to the rarity 
of these tumours. Diagnosis is further confirmed 
by immunohistochemical analysis as myopericytes 
are immunoreactive for smooth muscle actin and 
CD34, but rarely for desmin.6 However, no data 
exist for the follow-up or staging of these tumours. 
In cases of superficial myopericytoma with classic 
histological features, complete excision is curative. 
When these tumours are located in visceral 
organs additional staging is often performed by 
imaging studies. However, the prognosis of benign 
myopericytomas tends to be good. 
Malignant myopericytomas may present as a 
primary metastatic disease, or may rapidly 
metastasise as described above. Broad excision 
of these lesions with high mitotic index is the 
treatment of choice. Despite broad resection, 
the prognosis of a malignant myopericytoma 
remains unclear. Out of the five cases described by 
McMenamin and Fletcher,12 three patients died 
within the first year. The two surviving patients 
showed varying status; one developed liver 
metastases during the follow-up period of 
14 months, and the other survived with no evidence 
of recurrent or metastatic disease after surgical 
removal of the lesion. In another report from 2006, 
a subcutaneous malignant myopericytoma of the 
lower leg was treated by resection without any 
evidence of recurrent or metastatic disease. The 
follow-up period was undefined.5 Two recent papers 
have reported cases of malignant myopericytomas, 
one in the left atrium and one in the dura mater. 
Of these papers, the former reported metastases to 
the brain, skeletal system, and liver after 8 months, 
while the latter paper reported no evidence of 
recurrent or metastatic disease after 18 months.13,14
Until recently, there were no data available about 
the value of adjuvant therapy in preventing local 
recurrence or metastases of this disease. One case 
report described wide excision of a deep-seated, 
intermuscular malignant myopericytoma followed 
by external beam radiation. However, the patient 
died after 7 months due to metastases to the 
liver, brain, heart, and skeletal system.12 Recent 
genetic testing has, in some cases, revealed 
BRAFV600E mutations.15 These mutations are 
present in 15% of benign myopericytomas, 33% 
of which were multifocal/infiltrative or recurrent. 
Anti–BRAFV600E therapy with vemurafenib disrupts 
angiogenetic and metabolic properties with 
downreglation of some extracellular matrix factors. 
Consequently, these molecules might be a useful 
adjuvant treatment for myopericytomas expressing 
BRAFV600E mutations. Screening for these mutations 
is therefore recommended. 
In our case report, the patient presented with 
a myopericytoma of the skin with atypical 
features. A broad resection was performed but no 
additional imaging studies were performed. In the 
years following, a tumour in the right kidney with 
similar histological features as the skin lesion but 
a higher degree of cytonuclear atypia occurred. 
We decided  to perform a resection of a kidney 
metastasis of a malignant myopericytoma of 
the skin. It is possible that the kidney lesion was 
already present when excision of the skin lesion 
was performed and gradually grew until it became 
symptomatic. As the kidney lesion had higher 
cellularity, an elevated mitotic index and more 
cytonuclear atypia, as well as necrosis, we believe 
that the kidney tumour was a metastasis and not 
the primary tumour. As no BRAFV600E mutation was 
found, and no other site of metastatic deposit was 
seen, no adjuvant therapy could be given. Three 
months after excision of the kidney metastasis a 
PET CT scan showed no evidence of metastases. 
CONCLUSION
We report the first case of a malignant 
myopericytoma with metastasises to the kidney. 
Therefore, the traditional view that urinary 
myopericytoma are benign primary lesions needs 
to be updated.
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